These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8811720)
21. Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Wadenberg ML; Hillegaart V Neuropharmacology; 1995 May; 34(5):495-9. PubMed ID: 7566483 [TBL] [Abstract][Full Text] [Related]
23. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Ishikane T; Kusumi I; Matsubara R; Matsubara S; Koyama T Eur J Pharmacol; 1997 Feb; 321(2):163-9. PubMed ID: 9063684 [TBL] [Abstract][Full Text] [Related]
24. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076 [TBL] [Abstract][Full Text] [Related]
26. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Wadenberg MG; Browning JL; Young KA; Hicks PB Pharmacol Biochem Behav; 2001 Mar; 68(3):363-70. PubMed ID: 11325387 [TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965 [TBL] [Abstract][Full Text] [Related]
28. Supraspinal mediation of dopamine-serotonin interactions in extrapyramidal motor functions in the rat. Wadenberg ML; Hillegaart V; Berge OG Neuroreport; 1993 Jan; 4(1):59-61. PubMed ID: 8384019 [TBL] [Abstract][Full Text] [Related]
30. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387 [TBL] [Abstract][Full Text] [Related]
31. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993 [TBL] [Abstract][Full Text] [Related]
32. A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Carter CJ; Pycock CJ Naunyn Schmiedebergs Arch Pharmacol; 1978 Sep; 304(2):135-9. PubMed ID: 568219 [TBL] [Abstract][Full Text] [Related]
33. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice. Egashira N; Matsuda T; Koushi E; Mishima K; Iwasaki K; Shoyama Y; Fujiwara M Eur J Pharmacol; 2006 Nov; 550(1-3):117-22. PubMed ID: 17022969 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418 [TBL] [Abstract][Full Text] [Related]
36. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Verma A; Kulkarni SK Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866 [TBL] [Abstract][Full Text] [Related]
37. Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. Elliott PJ; Close SP; Walsh DM; Hayes AG; Marriott AS J Neural Transm Park Dis Dement Sect; 1990; 2(2):79-89. PubMed ID: 1977409 [TBL] [Abstract][Full Text] [Related]
38. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Tada M; Shirakawa K; Matsuoka N; Mutoh S Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255 [TBL] [Abstract][Full Text] [Related]
39. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Millan MJ; Gressier H; Brocco M Eur J Pharmacol; 1997 Mar; 321(3):R7-9. PubMed ID: 9085054 [TBL] [Abstract][Full Text] [Related]
40. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]